Skip to main content
. Author manuscript; available in PMC: 2014 Apr 9.
Published in final edited form as: Circulation. 2013 Jan 31;127(9):997–1008. doi: 10.1161/CIRCULATIONAHA.112.000641

Figure 2.

Figure 2

Structural and functional benefits of transplantation of human induced pluripotent stem cell–derived vascular cells (hiPSC-VCs). A, At week 4 after infarction, the cell-treatment group showed significantly smaller infarct size (delayed-enhancement magnetic resonance imaging) than the myocardial infarction (MI) group. B, MI induced left ventricular hypertrophy, as evidenced by significantly increased left ventricular weight over body weight (LVW/BW). hiPSC-VC transplantation attenuated the left ventricular hypertrophy. C, MI induced dilation of the left ventricular chamber compared with the normal group. hiPSC-VC transplantation attenuated the chamber dilation. D, hiPSC-VC transplantation significantly improved the ejection fraction of infarcted swine hearts. E, Border zone (BZ) myocardium in postinfarcted swine hearts showed significant contractile dysfunction (systolic thickening fraction), which was significantly improved in response to hiPSC-VC transplantation. hiPSC-VC treatment also prevented the infarct zone (IZ) from bulging out during systole (negative thickening fraction). F, hiPSC-VC transplantation alleviated the abnormal myocardial wall stress in the BZ and IZ myocardium. G, Representative cardiac magnetic resonance images from normal, MI, and cell-treatment groups at end systole (left) and end diastole (right). #P<0.05 vs normal group; *P<0.05 vs MI group. Quantification of cardiac functional parameters was based on normal hearts (n=10), MI hearts (n=9), and hearts treated with cell therapy (n=9). LVEDV indicates left ventricular end-diastolic volume; and RZ, remote zone.